0000-0003-2840-6398 About
I am an Indian American scientist with extensive experience in discovery and development of novel biotherapeutics that benefit the patients with unmet medical needs. I am passionate about using science and technology to mitigate challenges towards bringing biotherapeutics to market faster, more often, and at affordable costs.
I am using my expertise in computational biology, bioinformatics, computational biophysics, and data science to promote Biopharmaceutical Informatics, in silico developability assessments, and digital transformation in the biopharmaceutical industry. I have come up with a strategic vision, Biopharmaceutical Informatics.
Biopharmaceutical Informatics calls for syncretic use of Computational Biophysics, Biomolecular experiments, Information technology, and AIML towards improving the productivity of biologic drug discovery and development projects. In recent years, Biopharmaceutical Informatics has emerged as a field on its own. I am also working on democratizing biologic drug discovery via DAbI (Discovery of Antibodies in-silico). Once fully developed, this will be a paradigm shift in our industry.
I have so far contributed 116 research papers, reviews and book chapters. These publications have received more than 12,000 citations (h-index = 52; i10-index = 92; 29 cited 100 or more times, and 1 with more than 1200 citations). I have also edited two books entitled "Developability of Biotherapeutics: Computational Approaches", and "Biopharmaceutical Informatics: Learning How to Discover Developable Biotherapeutics". Both books have been published by Taylor and Francis. I have received numerous awards over my career including the 2014 Ebert Prize from American Pharmacists Association.
I have mentored numerous graduate students, postdoctoral fellows, and colleagues in the industry. I am also experienced at recruiting, supervising, and nurturing talent. I am particularly adept at leading cross-functional and international teams and forging academic-industry collaborations.
I am an associate Editor for mAbs, a Taylor & Francis Journal and a frequently invited speaker at the conferences in biopharmaceutical industry.
In summary my professional experience, since completing doctorate, spans 27 years in Government, Academia and Industry.
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (123)
- Amylo-Pipe: an integrated web server for mechanistic and kinetic prediction of protein and peptide aggregation Save
- An intrinsic sequence-structural profile for mRNA-delivered therapeutic antibodies Save
- How to think about designing smart antibodies in the age of genAI: integrating biology, technology, and experience Save
- Investigating Local Sequence‐Structural Attributes of Amyloidogenic Light Chain Variable Domains Save
- A Pharmacophore-Based Method for Rapid and Accurate Virtual Screening of Antibody Libraries against Antigens Save
- Quantum Machine Learning in Drug Discovery: Applications in Academia and Pharmaceutical Industries Save
- Biopharmaceutical Informatics: An Introduction. Save
- Computational biophysical analyses of antibody structure-function relationships with emphasis on therapeutic antibody-based biologics. Save
- Use of molecular simulations to understand structural dynamics of antibodies. Save
- Biopharmaceutical Informatics Save
- Conserved heavy/light contacts and germline preferences revealed by a large-scale analysis of natively paired human antibody sequences and structural data Save
- Deep learning-based design and experimental validation of a medicine-like human antibody library Save
- Deciphering the modulatory role of mutations in protein aggregation through in silico methods Save
- Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions Save
- Best practices for machine learning in antibody discovery and development Save
- LAP: Liability Antibody Profiler by sequence & structural mapping of natural and therapeutic antibodies Save
- Editorial: Progress and challenges in computational structure-based design and development of biologic drugs Save
- Biopharmaceutical Informatics: A Strategic Vision for Discovering Developable Biotherapeutic Drug Candidates Save
- Assessing developability early in the discovery process for novel biologics Save
- Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics Save